The global Lung Cancer Surgery Market is estimated to be valued at US$ 6.40 Bn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Lung cancer surgery is performed to remove cancerous tumors from the lungs. Some of the common types of lung cancer surgeries include lobectomy, pneumonectomy, and wedge resection. These surgeries help eliminate cancer cells, improve lung function, and provide long term survival and cure to the patients.

Market key trends:
One of the key trends in the lung cancer surgery market is the growing adoption of augmented reality. Augmented reality offers real-time visualization of internal organs during complex lung cancer procedures. It allows surgeons to see through tissues and visualize tumors, blood vessels, and other structures during surgery. This enhances precision and reduces chances of error. AR integrated with pre-operative CT/MRI scans helps navigate complex anatomical structures and plan surgery in advance. It has resulted in improved surgical outcomes for patients undergoing lung cancer resection procedures.

Segment Analysis
The global lung cancer surgery market is segmented by procedure, cancer type, and end user. Based on procedure, the thoracotomy segment holds the largest share in the market and is expected to witness significant growth over the forecast period. Thoracotomy provides direct access to various areas of the lungs and is commonly used for lung resection procedures like lobectomy and pneumonectomy. Based on cancer type, the non-small cell lung cancer segment dominates the market owing to its high prevalence. Around 85% of all lung cancers are non-small cell types.

Key Takeaways
Global Lung Cancer Surgery Market Size is expected to witness high growth, exhibiting a CAGR of 5.8% over the forecast period, due to increasing lung cancer incidence and adoption of minimally invasive surgical procedures.

Regional analysis: North America dominates the global lung cancer surgery market holding around 40% of the market share. This is attributed to advanced healthcare infrastructure and higher accessibility to advanced treatment options in the region. The Asia Pacific region is expected to grow at the fastest rate due to increasing healthcare spending, improving access to healthcare facilities, and rising per capita income.

Market size: The global lung cancer surgery market size was valued at US$ 6.40 Billion in 2023 and is expected to reach US$ 9.98 Billion by 2030.

Key players: Key players operating in the lung cancer surgery market are Ethicon (Johnson & Johnson), Medtronic, Intuitive Surgical, Olympus Corporation, Karl Storz, Teleflex Incorporated, Accuray Incorporated, AngioDynamics, CONMED Corporation, Trovagene, Varian Medical Systems, Medrobotics Corporation, Siemens Healthineers, Atricure, Inc., Novadaq Technologies Inc. Ethicon and Medtronic are the leaders in lung cancer surgery devices.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it